Together, we may propose that therapeutic strategies combining mitophagy blockade with metabolic interventions that force pyruvate toward mitochondrial oxidation (e.g., PDK1 inhibitors or lactate transport blockade) hold promise for disrupting tumor plasticity and overcoming chemoresistance in osteosarcoma. This evidence concerns the gene PDK1 and neoplasm.